Empirical Asset Management LLC Buys Shares of 43,520 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Empirical Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,520 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,359,000. Empirical Asset Management LLC owned about 0.07% of Jazz Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares during the period. Venturi Wealth Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,253 shares of company stock worth $1,001,434. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:JAZZ opened at $122.62 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.41 billion, a P/E ratio of 17.27, a P/E/G ratio of 0.88 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The stock’s fifty day simple moving average is $122.83 and its 200-day simple moving average is $114.50.

Analysts Set New Price Targets

Several equities research analysts have commented on JAZZ shares. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.